James Allen, MD
Dermatology · Leawood, KSNPI 1548266554
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,102 and has fallen 66.4% since, to $370 in 2025.
Across 167 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$510
- Amgen$360
- Sanofi$294
- Regeneron Healthcare Solutions, Inc.$270
- Pfizer$227
- Lilly USA, LLC$216
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,25299%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $510 |
| Amgen | 15 | $360 |
| Sanofi | 13 | $294 |
| Regeneron Healthcare Solutions, Inc. | 12 | $270 |
| Pfizer | 10 | $227 |
| Lilly USA, LLC | 10 | $216 |
| Johnson & Johnson(2 entities) | 11 | $212 |
| Dermavant Sciences, Inc. | 15 | $189 |
| Incyte Corporation | 5 | $124 |
| Sun Pharmaceutical Industries Inc. | 5 | $122 |
| Galderma Laboratories, L.p. | 5 | $99 |
| UCB, Inc. | 4 | $90 |
| Novartis | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 3 | $73 |
| Organon | 4 | $54 |
| LEO Pharma Inc. | 3 | $41 |
| Almirall LLC | 2 | $39 |
| Sanofi-aventis U.S. LLC | 1 | $35 |
| Genentech USA, Inc. | 2 | $35 |
| Kerecis Limited | 2 | $34 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $31 |
| Mayne Pharma Commercial LLC | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| DUSA Pharmaceuticals, Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $17 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
| EPI Health, LLC | 1 | $12 |
| Prugen, Inc. Pharmaceuticals | 1 | $7 |
How this compares
$3,287 in reported general payments places this provider in the 60th percentile of 82 dermatology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 21 | $118,492 |
| Dupixent PenDupilumab | 11 | $38,935 |
| Fluorouracil | 86 | $6,142 |
| Betamethasone Dipropionate | 143 | $4,915 |
| Clobetasol Propionate | 44 | $2,291 |
| Ketoconazole | 113 | $1,745 |
| Metronidazole | 26 | $1,468 |
| ValacyclovirValacyclovir Hcl | 21 | $1,122 |
| Imiquimod | 80 | $1,006 |
| Triamcinolone Acetonide | 91 | $917 |
| Doxycycline Hyclate | 27 | $708 |
| Gabapentin | 15 | $654 |
| Acyclovir | 17 | $415 |
| Hydroxyzine Hcl | 19 | $309 |
| Finasteride | 22 | $257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $360 | $118,49221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 82 dermatology providers in Kansas.
Other dermatology in Leawood
- Kyle AndersonLeawood$23K
- Celeste AngelLeawood$6K
- Karen NeubauerLeawood$6K
- Colin RuffLeawood$3K
- Anne BlakeLeawood$3K
- Viseslav Tonkovic CapinLeawood$851
- David KaplanOverland Park$489K
- Meena SinghOverland Park$181K
- Daniel AiresKansas City$83K
- Dominic WuShawnee Mission$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.